Posted by Michael Wonder on 26 Jul 2026
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration
24 July 2026 - Roche announced today that the EMA’s CHMP has recommended the approval of Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of neovascular age-related macular degeneration.
Susvimo is intended for continuous release into the vitreous using the Contivue implant.
